195 related articles for article (PubMed ID: 38340557)
1. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
[TBL] [Abstract][Full Text] [Related]
2. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
[TBL] [Abstract][Full Text] [Related]
3. hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis.
Di Modugno F; Spada S; Palermo B; Visca P; Iapicca P; Di Carlo A; Antoniani B; Sperduti I; Di Benedetto A; Terrenato I; Mottolese M; Gandolfi F; Facciolo F; Chen EI; Schwartz MA; Santoni A; Bissell MJ; Nisticò P
Oncogene; 2018 Oct; 37(42):5605-5617. PubMed ID: 29907768
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer.
Bria E; Di Modugno F; Sperduti I; Iapicca P; Visca P; Alessandrini G; Antoniani B; Pilotto S; Ludovini V; Vannucci J; Bellezza G; Sidoni A; Tortora G; Radisky DC; Crinò L; Cognetti F; Facciolo F; Mottolese M; Milella M; Nisticò P
Oncotarget; 2014 Nov; 5(22):11054-63. PubMed ID: 25373410
[TBL] [Abstract][Full Text] [Related]
5. The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation.
Melchionna R; Spada S; Di Modugno F; D'Andrea D; Di Carlo A; Panetta M; Mileo AM; Sperduti I; Antoniani B; Gallo E; Lawlor RT; Piemonti L; Visca P; Milella M; Grazi GL; Facciolo F; Chen E; Scarpa A; Nisticò P
EMBO Rep; 2020 Nov; 21(11):e50078. PubMed ID: 32909687
[TBL] [Abstract][Full Text] [Related]
6. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.
Di Modugno F; Iapicca P; Boudreau A; Mottolese M; Terrenato I; Perracchio L; Carstens RP; Santoni A; Bissell MJ; Nisticò P
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19280-5. PubMed ID: 23129656
[TBL] [Abstract][Full Text] [Related]
7. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
[TBL] [Abstract][Full Text] [Related]
8. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
[TBL] [Abstract][Full Text] [Related]
9. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma.
Tanaka N; Yoshida H; Suzuki Y; Harigaya K
Int J Oncol; 2014 Nov; 45(5):1921-8. PubMed ID: 25109497
[TBL] [Abstract][Full Text] [Related]
10. CD28/PD1 co-expression: dual impact on CD8
Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
[TBL] [Abstract][Full Text] [Related]
11. The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome.
Melchionna R; Iapicca P; Di Modugno F; Trono P; Sperduti I; Fassan M; Cataldo I; Rusev BC; Lawlor RT; Diodoro MG; Milella M; Grazi GL; Bissell MJ; Scarpa A; Nisticò P
Oncoimmunology; 2016; 5(12):e1221556. PubMed ID: 28123868
[TBL] [Abstract][Full Text] [Related]
12. Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade.
Miyai Y; Sugiyama D; Hase T; Asai N; Taki T; Nishida K; Fukui T; Chen-Yoshikawa TF; Kobayashi H; Mii S; Shiraki Y; Hasegawa Y; Nishikawa H; Ando Y; Takahashi M; Enomoto A
Life Sci Alliance; 2022 Jun; 5(6):. PubMed ID: 35236758
[TBL] [Abstract][Full Text] [Related]
13. GLMEEMSAL epitope common in different isoforms of hMena elicits in vitro activation of cytotoxic T cells and stimulates specific antitumor immunity in BALB/c mice.
Don-López CA; Monroy-García A; Weiss-Steider B; Rocha-Zavaleta L; Hernández-Montes J; García-Rocha R; Mora-García ML
Int Immunopharmacol; 2018 Mar; 56():291-300. PubMed ID: 29414664
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta.
O'Connor RA; Martinez BR; Koppensteiner L; Mathieson L; Akram AR
Front Immunol; 2023; 14():1221532. PubMed ID: 37520560
[TBL] [Abstract][Full Text] [Related]
15. Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients.
Germain C; Devi-Marulkar P; Knockaert S; Biton J; Kaplon H; Letaïef L; Goc J; Seguin-Givelet A; Gossot D; Girard N; Validire P; Lefèvre M; Damotte D; Alifano M; Lemoine FM; Steele KE; Teillaud JL; Hammond SA; Dieu-Nosjean MC
Front Immunol; 2021; 12():626776. PubMed ID: 33763071
[TBL] [Abstract][Full Text] [Related]
16. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.
He M; He Q; Cai X; Liu J; Deng H; Li F; Zhong R; Lu Y; Peng H; Wu X; Chen Z; Lao S; Li C; Li J; He J; Liang W
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072348
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling.
Johansson-Percival A; Ganss R
Front Immunol; 2021; 12():674375. PubMed ID: 34122434
[TBL] [Abstract][Full Text] [Related]
19. Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer.
Rakaee M; Kilvaer TK; Jamaly S; Berg T; Paulsen EE; Berglund M; Richardsen E; Andersen S; Al-Saad S; Poehl M; Pezzella F; Kwiatkowski DJ; Bremnes RM; Busund LR; Donnem T
Br J Cancer; 2021 May; 124(10):1680-1689. PubMed ID: 33723388
[TBL] [Abstract][Full Text] [Related]
20. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]